ABVX: Rega marang dodolan Abivax Pharma

ABIVAX is an ambitious biotech developer gaining recognition through successful tests of anti-inflammatory agents. However, a lack of sales and limited capital leave the company vulnerable to the outcome of final trials. Growth is accelerating through partnerships with clinics and research centers. The company's normalized P/S helps assess the balance between demand and revenue, where the level captures the current state of the asset.

The P/S multiple is calculated as the ratio of market capitalization to annual revenue, determining the cost of each ruble of sales to assess whether an asset is overvalued. For ABIVAX (ABVX), the market P/S multiple reflects market expectations for the commercial success of obefazimod, where the current business valuation depends directly on clinical trial results and the prospects of partnerships with Big Pharma.